UBS Maintains a 'Buy' on Linear Technology (LLTC); Under Shipping Industrial End Demand
Tweet
Share
E-mailGet Alerts LLTC Hot Sheet
Price: $65.00 --0%
Rating Summary:
1 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
1 Buy, 16 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
UBS maintains a 'Buy' on Linear Technology (NASDAQ: LLTC) price target lowered $1 to $33.
UBS analyst says, "We believe LLTC is under-shipping end demand as its forecast of -11% seq revenue growth for CQ4 is tracking well below our basket of industrial companies which our UBS industrial analysts estimate will grow ~4% in CQ4. Although demand remains weak, we believe we are closer to the bottom and expect a resumption of growth from early 2012."
"For F2Q, we now forecast Rev/EPS of $294m/$0.39, down from prior estimates of $338m/$0.50. For F2012, we lower our Rev/EPS estimates to $1,250m/$1.72 from $1,384m/$2.05 and for FY2013 to $1,350m/$2.00 from $1,507m/$2.34."
For more ratings news on Linear Technology click here and for the rating history of Linear Technology click here.
Shares of Linear Technology closed at $30.23 yesterday.
UBS analyst says, "We believe LLTC is under-shipping end demand as its forecast of -11% seq revenue growth for CQ4 is tracking well below our basket of industrial companies which our UBS industrial analysts estimate will grow ~4% in CQ4. Although demand remains weak, we believe we are closer to the bottom and expect a resumption of growth from early 2012."
"For F2Q, we now forecast Rev/EPS of $294m/$0.39, down from prior estimates of $338m/$0.50. For F2012, we lower our Rev/EPS estimates to $1,250m/$1.72 from $1,384m/$2.05 and for FY2013 to $1,350m/$2.00 from $1,507m/$2.34."
For more ratings news on Linear Technology click here and for the rating history of Linear Technology click here.
Shares of Linear Technology closed at $30.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
